Correspondence 0001628280-22-029839 from Context Therapeutics Inc. (CNTX) (CIK 0001842952) (CNTX)
Context Therapeutics Inc. (CNTX) (CIK 0001842952)
Date: Nov. 14, 2022 · CIK: 0001842952 · Accession: 0001628280-22-029839
AI Filing Summary & Sentiment
File numbers found in text: 333-268266
Letter
Document
Context Therapeutics Inc.
2001 Market Street, Suite 3915, Unit #15
Philadelphia, Pennsylvania 19103
November 14, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-268266
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Context Therapeutics Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on November 16, 2022, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Walter J. Mostek, Esq. of Faegre Drinker Biddle & Reath LLP at (215) 988-3330. Thank you for your assistance and cooperation in this matter.
Very truly yours,
CONTEXT THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm Document Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 November 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-268266 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Context Therapeutics Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on November 16, 2022, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Walter J. Mostek, Esq. of Faegre Drinker Biddle & Reath LLP at (215) 988-3330. Thank you for your assistance and cooperation in this matter. Very truly yours, CONTEXT THERAPEUTICS INC. By: /s/ Martin Lehr Martin Lehr Chief Executive Officer cc: Jennifer Minai-Azary, Chief Financial Officer, Context Therapeutics Inc. Alex Levit, Chief Legal Officer, Context Therapeutics Inc. Walter J. Mostek, Esq., Faegre Drinker Biddle & Reath LLP